07 . 10 .2022
Press release
New data from Galderma's aesthetics portfolio to be presented at 2022 ASDS Annual Meeting
03 . 10 .2022
Press release
Galderma and National Breast Cancer Foundation Announce Continued Partnership to Launch Campaign Elevating Skin Stories of Breast Cancer Survivors
16 . 09 .2022
Press release
Galderma debuts the Sensitive Skincare Faculty, a global expert group to improve understanding and management of sensitive skin
06 . 09 .2022
Press release
Galderma showcases its continued commitment to innovation in dermatology with new data to be presented at 2022 EADV congress
25 . 08 .2022
Press release
Galderma delivers strong H1 2022 results and continued innovation across its leading dermatology portfolio
30 . 06 .2022
Press release
Galderma and Children’s Skin Disease Foundation Celebrate Decade-Long Partnership
22 . 06 .2022
Press release
Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis
10 . 06 .2022
Press release
Galderma announces positive results in two phase III studies for a novel liquid formulation botulinumtoxinA (RelabotulinumtoxinA) for the treatment of glabellar lines (frown) and lateral canthal lines (crow’s feet)